Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Amicus on July 31 and set a price target of $17.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz has given his Buy rating due to a combination of factors that highlight Amicus’s strong performance and growth potential. The company reported a significant increase in sales for both its enzyme replacement therapy and enzyme stabilizer products, exceeding both consensus and internal estimates. This growth is particularly notable given the previous pricing challenges faced in the UK, indicating a robust recovery and expansion in international markets.
Additionally, Amicus’s strategic plans for further international launches, including in countries with high prevalence of Pompe disease, bolster its growth outlook. The company’s guidance for fiscal year 2025 remains optimistic, with expectations of substantial revenue growth. Furthermore, the ongoing pivotal study for DMX-200 in treating focal segmental glomerulosclerosis is progressing well, adding to the company’s potential for future success. These factors collectively support Schwartz’s positive outlook and Buy rating for Amicus.
In another report released on August 1, J.P. Morgan also maintained a Buy rating on the stock with a $18.00 price target.
FOLD’s price has also changed moderately for the past six months – from $9.580 to $5.990, which is a -37.47% drop .